Kaizen Advisory’s Boston Scientific BSX Stock Holding History

Kaizen Advisory’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$128K	Buy	3,632 +333	+10%	+$12.1K	0.09%	192
2018 Q3	$127K	Hold	3,299	–	–	0.07%	202
2018 Q2	$108K	Buy	3,299 +1,962	+147%	+$59.2K	0.05%	216
2018 Q1	$37K	Hold	1,337	–	–	0.04%	234
2017 Q4	$33K	Buy	+1,337	New	+$36.9K	0.02%	246

Other funds holding BSX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Kaizen Advisory's BSX Position: Q4 2018 in Review

Kaizen Advisory increased its Boston Scientific (BSX) stake by 10% in Q4 2018, buying an estimated $12.1K and bringing the position to 3,632 shares worth $128K. The position accounts for 0.09% of the portfolio, ranked #192.

Kaizen Advisory first reported a position in BSX in Q4 2017 and has held it in 5 quarters since. 730 funds tracked by Wall St. Rank hold BSX as of Q4 2018.

Kaizen Advisory held 3,632 shares of Boston Scientific worth $128K as of Q4 2018.
Kaizen Advisory bought 333 Boston Scientific shares in Q4 2018, an estimated $12.1K.
Boston Scientific made up 0.09% of Kaizen Advisory's portfolio in Q4 2018, its #192 holding.
Kaizen Advisory first reported a position in Boston Scientific in Q4 2017 and has held it in 5 quarters since.
730 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2018.

Based on Kaizen Advisory's 13F filing for Q4 2018, filed 15 Feb 2019.